Also, remember that Mr. Bond was CFO at Sandoz, and Novartis still has a familiar face, Harry Kirsch, as CFO.
I am very happy to welcome Colin Bond to Sandoz as our new CFO. Colin has started this week with us. He joins Sandoz from Vifor Pharma where he was CFO from May 2016 until January 2022. He played a key role in the separation of Vifor and Galenica on the SIX Swiss Exchange in 2017. Previously he was the CFO of Evotec AG, a global drug discovery company listed on the Frankfurt Stock Exchange as part of the MDAX, from 2010 to 2016. During his early career, Colin worked as a pharmacist, auditor, and management consultant for Procter & Gamble, Arthur Andersen, and PricewaterhouseCoopers, respectively. Colin is a Fellow of the Institute of Chartered Accountants in England and Wales and a member of the Royal Pharmaceutical Society of Great Britain. He is also a Board member of Siegfried Holding AG, and of BioPharma Credit PLC, a company quoted on the Main Market of the London Stock Exchange. Colin will strengthen the capabilities within our finance team aligned to the possible outcomes of the Sandoz strategic review. In his new role, Colin will report to me directly and with a functional line to Novartis CFO Harry Kirsch. – Welcome, Colin!